01 / Contract Profile
75F40122C00125 Federal Contract Award
Agency code 7524
THE PURPOSE OF THIS MODIFICATION IS TO DE-OBLIGATE FUNDS, CANCEL NON-FUNDED ITEMS 4 AND 5, THEN CLOSE OUT THE CONTRACT.
02 / Contract Size and Status
What is the recorded size and timing of this contract?
03 / Spending Trend
75F40122C00125 contract spending by fiscal year
Annual net obligations across the complete period available for this agency and PIID, from the first recorded fiscal year through the latest contract action.
Latest fiscal year obligations-$729.9K
FY 2026Net obligationsComplete recorded range
| Fiscal year | Net obligations | Actions | Change |
|---|---|---|---|
| FY 2022 | $685.2K | 2 | — |
| FY 2023 | $303.7K | 1 | −55.7% |
| FY 2024 | $303.7K | 1 | +0.0% |
| FY 2025 | $0 | 2 | −100.0% |
| FY 2026 | -$729.9K | 1 | — |
04 / Federal Buyer
Which organization manages this contract?
| Department | Contracting agency | Contracting office |
|---|---|---|
| HEALTH AND HUMAN SERVICES, DEPARTMENT OF | FOOD AND DRUG ADMINISTRATION | FDA OFFICE OF ACQ GRANT SVCS |
05 / Contractor
Who holds this federal contract?
ALBANY COLLEGE OF PHARMACY & HEALTH SCIENCES
UEI LCFLMPUNNGJ3 · CAGE 1M9T7
06 / NAICS Industries
Which industries classify this contract?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| 541714 | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) | $562.7K | 7 | 100.0% |
07 / Products and Services
What products or services were purchased?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| U004 | EDUCATION/TRAINING- SCIENTIFIC/MANAGEMENT | $562.7K | 7 | 100.0% |
08 / Place of Performance
Where is the work recorded?
SILVER SPRING, MONTGOMERY, MARYLAND, UNITED STATES
ZIP 209930002
09 / Contract Actions
What modifications and obligations were recorded?
| Signed date | Modification | Obligation | Contracting office | NAICS | PSC |
|---|---|---|---|---|---|
| Jun 4, 2026 | P00006 | -$729.9K | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541714 | U004 |
| Aug 6, 2025 | P00005 | $0 | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541714 | U004 |
| Aug 1, 2025 | P00004 | $0 | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541714 | U004 |
| May 10, 2024 | P00003 | $303.7K | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541714 | U004 |
| Jul 3, 2023 | P00002 | $303.7K | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541714 | U004 |
| Nov 8, 2022 | P00001 | $0 | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541714 | U004 |
| Sep 16, 2022 | Base action | $685.2K | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541714 | U004 |
10 / Reading the Contract
How should this award record be interpreted?
Read the PIID as a transaction history, not as a single purchase price. Net obligations combine the base action with later increases, reductions, corrections, and deobligations recorded under the same contract.
Verify the buyer
Agency and office identify who manages the procurement relationship.
Follow modifications
Each action can change funding, scope, dates, or administrative terms.
Compare the market
Use NAICS, PSC, and the contractor profile to identify related buyers and competitors.